{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:16:25Z","timestamp":1783199785877,"version":"3.54.6"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:26:25Z","timestamp":1771536385000},"page":"619-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world Adherence to European Association of Urology\u2013recommended Non\u2013muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-2306","authenticated-orcid":false,"given":"Mattia","family":"Longoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zaurito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tremolada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazareno","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Szostek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Ca\u00f1o","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Lafuente Puentedura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Del Olmo Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.02.005_b0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.005_b0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.urolonc.2020.06.013","article-title":"Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: a systematic review","volume":"38","author":"Mori","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.005_b0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bju.15336","article-title":"What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?","volume":"128","author":"Dunsmore","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.02.005_b0030","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.euf.2017.09.002","article-title":"Discrepancy between European Association of Urology guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey","volume":"5","author":"Hendricksen","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.02.005_b0035","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/iju.15294","article-title":"Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: a retrospective multicenter study","volume":"30","author":"Sato","year":"2023","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0045","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bju.13102","article-title":"Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical bacillus Calmette-Gu\u00e9rin","volume":"116","author":"Baltac\u0131","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.02.005_b0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0391560319899303","article-title":"How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices","volume":"87","author":"Sountoulides","year":"2020","journal-title":"Urologia"},{"key":"10.1016\/j.euo.2026.02.005_b0055","doi-asserted-by":"crossref","unstructured":"Scilipoti P, Longoni M, De Angelis M, et al. Long-term oncological outcomes for patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin (BCG): a comparative analysis of adequate versus inadequate BCG treatment. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2025.04.033.","DOI":"10.1016\/j.euf.2025.04.033"},{"key":"10.1016\/j.euo.2026.02.005_b0060","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1541-0420.2006.00528.x","article-title":"Estimating average annual percent change for disease rates without assuming constant change","volume":"62","author":"Fay","year":"2006","journal-title":"Biometrics"},{"key":"10.1016\/j.euo.2026.02.005_b0065","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.euo.2023.12.008","article-title":"Comparative effectiveness of neoadjuvant pembrolizumab versus cisplatin-based chemotherapy or upfront radical cystectomy in patients with muscle-invasive urothelial bladder cancer","volume":"7","author":"Li","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.005_b0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post\u2013transurethral resection of bladder tumor intravesical chemotherapy prevents non\u2013muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0080","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/14737140.2025.2537793","article-title":"Implementation challenges of single-instillation intravesical chemotherapy following transurethral resection of bladder tumor","volume":"25","author":"Malshy","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.euo.2026.02.005_b0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.21037\/tau.2018.08.20","article-title":"Single postoperative instillation for non-muscle invasive bladder cancer: are there still any indication?","volume":"8","author":"Zamboni","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0090","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2011.12.056","article-title":"National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer","volume":"187","author":"Cookson","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0095","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.005_b0100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.euo.2020.03.004","article-title":"Bacillus Calmette-Gu\u00e9rin retains clinically relevant viability for up to 72 hours after reconstitution: potential implications for clinical practice in times of shortage","volume":"4","author":"Brooks","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.005_b0105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.euf.2023.07.002","article-title":"Repeat transurethral resection for non\u2013muscle-invasive bladder cancer: an updated systematic review and meta-analysis in the contemporary era","volume":"10","author":"Yanagisawa","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.02.005_b0115","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudj\u00f3nsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0120","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A systematic review and meta-analysis of chemoablation for non-muscle-invasive bladder cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.02.005_b0125","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bju.16780","article-title":"Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study","volume":"136","author":"Longoni","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.02.005_b0130","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1002\/cam4.3513","article-title":"Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"9","author":"Lu","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2026.02.005_b0135","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00345-024-05342-1","article-title":"The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer","volume":"42","author":"Scilipoti","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0140","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/Grade 3 bladder cancer treated with bacille Calmette-Gu\u00e9rin","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.02.005_b0150","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2020.06.051","article-title":"Enhanced quality and effectiveness of transurethral resection of bladder tumour in non\u2013muscle-invasive bladder cancer: a multicentre real-world experience from Scotland\u2019s Quality Performance Indicators Programme","volume":"78","author":"Mariappan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.005_b0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.euros.2022.09.025","article-title":"Implementing a checklist for transurethral resection of bladder tumor to standardize outcome reporting: when high-quality resection could influence oncological outcomes","volume":"48","author":"Diana","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.02.005_b0160","doi-asserted-by":"crossref","unstructured":"Scilipoti P, Zaurito P, Longoni M, et al. Efficacy and safety of checkpoint inhibitors combined with bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve high-risk non\u2013muscle-invasive bladder cancer: synthesis of evidence from the ALBAN, CREST, and POTOMAC trials. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.022.","DOI":"10.1016\/j.eururo.2025.12.022"},{"key":"10.1016\/j.euo.2026.02.005_b0165","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/bju.16622","article-title":"Survival after trimodal therapy in octogenarians with organ\u2010confined urothelial bladder cancer","volume":"135","author":"Longoni","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.02.005_b0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.euo.2026.02.005_b0175","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.eursup.2009.06.003","article-title":"Transurethral resection of non\u2013muscle-invasive bladder cancer","volume":"8","author":"Babjuk","year":"2009","journal-title":"Eur Urol Suppl"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:42:34Z","timestamp":1783197754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931126000428"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Adherence to European Association of Urology\u2013recommended Non\u2013muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}